Target-specific CRISPR mutant
US11441135B2 · kind B2 · utility
0Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2018 |
| Grant date | Sep 13, 2022 |
| Priority date | — |
| Expiry date | Jul 16, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/20
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.